2023-505828-58-00CompletedPhase 1
CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 May 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 5 Jul 2023
- Start date
- 5 Dec 2023
- Lead sponsor
- Curis Inc.
- Diseases
- Acute myeloid leukemia
- EU CT number
- 2023-505828-58-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 24
- 8 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Technische Universität Dresden | Dresden | Germany | Completed |
| University Medical Center Hamburg-Eppendorf | Hamburg | Germany | Completed |
| University Hospital Jena KöR | Jena | Germany | Completed |
| Universitaet Leipzig | Leipzig | Germany | Completed |
| MD Anderson Cancer Center | Madrid | Spain | Completed |
| Hospital General Universitario Gregorio Marañón | Madrid | Spain | Completed |
| Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico | Bologna | Italy | Completed |
| Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l | Meldola | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.